Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > We are going after liquid(LNO) and nasal for now.

<< Previous

Bullboard Posts

Next >>

Comment by Scottyon Mar 13, 2021 10:26pm

99 Views

Post# 32794156

RE:We are going after liquid(LNO) and nasal for now.

Andew Salzman says his version of NO is better than his competitor, well I'm shocked. Ignore that SaNOtize is further along and more recognized. Coming late to the party might as well mean not coming at all.

Besides, how does KLY plan to pay for the upcoming research? Oh yeah, take a wild guess lol. Dude, you're the gift that keeps on giving.

<< Previous

Bullboard Posts

Next >>

Level up your trading with BMO InvestorLine’s enhanced features